Table 1

The most typical antipsychotics

InterventionOutcomes
ExperimentalControlImmediateShort term (0–6 weeks)Medium term (7 weeks to 6 months)Long term (>6 months)
RR = Relative risk—the experimental event rate/control event rate; CI = 95% confidence intervals—an estimate of the precision of RR; ⇓ = decreased; ⇑ = increased; ⇔ = no clear difference.
Chlorpromazine17PlaceboMovement disorders ⇑ (RR=3; CI 1.3 to 8)Improved ⇑ (RR=1.6; CI 1.3 to 1.8)Improved ⇑ (RR=2; CI 1.8 to 2.4)Relapse ⇓ (RR=0.6; CI 0.5 to 0.7)
1646 participants1470 participantsRelapse ⇓ (RR=0.3; CI 0.1 to 0.8)Relapse ⇓ (RR=0.5; CI 0.4 to 0.6)Attrition ⇔ (RR=1.0; CI 0.7 to 1.6)
Attrition ⇓ (RR=0.7; CI 0.6 to 0.9)Attrition ⇓ (RR=0.6; CI 0.5 to 0.8)Movement disorders ⇑ (RR=2.8; CI 1.4 to 6)
Movement disorders ⇑ (RR=1.8; CI 1.1 to 4.7)Movement disorders ⇑ (RR=2; CI 1.5 to 2.7)Weight ⇑ (OR=5; CI 2 to 10)
Sedation ⇑ (RR=2.3; CI 1.8 to 3)
Zuclopenthixol acetate26Chlorpromazine, haloperidol, clothiapineImproved ⇔ (RR=1; CI 0.9 to 1.1)
234 participants179 participantsRequiring re-dosing ⇔ (RR=1.5; CI 0.8 to 2.9)
Attrition ⇔ (RR=0.7; CI 0.2 to 2.1)
Haloperidol decanoate23Oral haloperidolImproved ⇔ (RR=0.9; CI 0.6 to 1.4)
11 participants11 participants
Haloperidol decanoate23Other depotsRelapse ⇔ (RR=1.2; CI 0.7 to 1.9)
187 participants184 participantsAttrition ⇔ (RR=0.9; CI 0.6 to 1.4) Movement disorders ⇔ (RR=0.9; CI 0.8 to 1.1)